Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking

Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking

Bibliographic Details
Main Authors:	Ryan M. Centko, Graeme W. Carlile, Isabel Barne, Brian O. Patrick, Polina Blagojevic, David Y. Thomas, Raymond J. Andersen
Format:	Article
Language:	English
Published:	American Chemical Society 2020-09-01
Series:	ACS Omega
Online Access:	http://dx.doi.org/10.1021/acsomega.0c02467

Similar Items

Unravelling druggable signalling networks that control F508del-CFTR proteostasis
by: Ramanath Narayana Hegde, et al.
Published: (2015-12-01)

Pyridazine Based Compounds with PARP-1 Inhibitory Activity
by: Norhan A. Abdelrahman, et al.
Published: (2023-12-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

Ouabain mimics low temperature rescue of F508del-CFTR in cystic fibrosis epithelial cells
by: Donglei eZhang, et al.
Published: (2012-10-01)

Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines
by: Sampson Heidi M, et al.
Published: (2013-01-01)

Serine-linked PARP1 auto-modification controls PARP inhibitor response.
by: Prokhorova, E, et al.
Published: (2021)

Combinations of PARP inhibitors with temozolomide drive PARP1 trapping and apoptosis in Ewing’s sarcoma
by: Gill, S, et al.
Published: (2015)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
by: Xia Ding, et al.
Published: (2022-07-01)

Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry
by: Isabelle Maxim, et al.
Published: (2010-04-01)

Latonduine-1-Amino-Hydantoin Hybrid, Triazole-Fused Latonduine Schiff Bases and Their Metal Complexes: Synthesis, X-ray and Electron Diffraction, Molecular Docking Studies and Antiproliferative Activity
by: Christopher Wittmann, et al.
Published: (2023-01-01)

The F508del-CFTR trafficking correctors elexacaftor and tezacaftor are CFTR-independent Ca2+-mobilizing agonists normalizing abnormal Ca2+ levels in human airway epithelial cells
by: Manuella Lévêque, et al.
Published: (2024-12-01)

PARP, transcription and chromatin modeling
by: Posavec Marjanović, M, et al.
Published: (2016)

Structural Comparative Modeling of Multi-Domain F508del CFTR
by: Eli Fritz McDonald, et al.
Published: (2022-03-01)

PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation
by: Kar, P, et al.
Published: (2024)

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
by: Zhiyan Zhan, et al.
Published: (2024-09-01)

Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods
by: Hongye Hu, et al.
Published: (2020-05-01)

A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma
by: Hui Li, et al.
Published: (2022-08-01)

Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A
by: Miquéias Lopes-Pacheco, et al.
Published: (2022-01-01)

New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage
by: Zongying Gu, et al.
Published: (2019-08-01)

PARP inhibitors in cancer diagnosis and therapy
by: Chan, C, et al.
Published: (2020)

Update on Combination Strategies of PARP Inhibitors
by: Zhuoqun Lin, et al.
Published: (2024-11-01)

PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01)

PARP inhibitors in metastatic prostate cancer
by: Amy K. Taylor, et al.
Published: (2023-04-01)

Structural implications for selective targeting of PARPs
by: Jamin D. Steffen, et al.
Published: (2013-12-01)

PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
by: Chaohua Liu, et al.
Published: (2024-05-01)

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
by: Chiho Kim, et al.
Published: (2020-08-01)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
by: Ymera Pignochino, et al.
Published: (2017-04-01)

Differential thermostability and response to cystic fibrosis transmembrane conductance regulator (CFTR) potentiators of human and mouse F508del-CFTR
by: Bose, S, et al.
Published: (2019)

A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells
by: Petar-Bogomil Kanev, et al.
Published: (2024-05-01)

PARP1pred: a web server for screening the bioactivity of inhibitors against DNA repair enzyme PARP-1
by: Tassanee Lerksuthirat, et al.
Published: (2023-01-01)

Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging
by: Jyothi Mahadevan, et al.
Published: (2023-01-01)

Biophysical characterisation of calumenin as a charged F508del-CFTR folding modulator.
by: Rashmi Tripathi, et al.
Published: (2014-01-01)

Farnesylation-dependent regulation of transcripts by PARP13
by: Uchima, Lilen
Published: (2016)

Beyond PARP—POLθ as an anticancer target
by: Higgins, G, et al.
Published: (2018)

PARP inhibitors alone or in combination for prostate cancer
by: María Dolores Fenor de la Maza, et al.
Published: (2024-08-01)

PARP inhibitors in non-ovarian gynecologic cancers
by: Italo Fernandes, et al.
Published: (2024-06-01)

Development of PARP inhibitors in advanced prostate cancer
by: Maria Teresa Bourlon, et al.
Published: (2024-01-01)

PARP inhibitors in prostate cancers, is it time for combinations?
by: Diego Teyssonneau, et al.
Published: (2024-05-01)

PARP inhibitors combined with radiotherapy: are we ready?
by: Chen Sun, et al.
Published: (2023-10-01)

Sensitizing HR-proficient cancers to PARP inhibitors
by: Elgene Lim, et al.
Published: (2017-11-01)